FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory B-ALL

The FDA has approved brexucabtagene autoleucel as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.

Read the full article here

Related Articles